Multifaceted Usage of HPV Related Tests and Products in the Management of Cervical Cancer - a Review

  • Nalliah, Sivalingam (Division of Human Development and Population Health, Clinical School, International Medical University) ;
  • Karikalan, Barani (School of Medicine, International Medical University) ;
  • Kademane, Kumaraswamy (School of Medicine, International Medical University)
  • Published : 2015.04.03


HPV viruses are integral to the development of cervical cancer. The pathogenesis has been extensively studied. To date, numerous HPV tests and products have been developed and successfully utilized in diagnosis, treatment and prevention of cervical cancer. The HPV DNA test, when combined with other routine cervical cancer screening and diagnostic tests namely exfoliative cytology, visual inspection with acetic acid (VIA) and colposcopy has increased the detection rate of cervical cancer. HPV DNA products could also be measured in other body fluids like urine, lymph node tissue, and serum. HPV association could also be quantified by measuring other parameters like HPV mRNA, viral load, viral integration and methylation status. Vaccination against HPV has been found to decrease the incidence of cervical cancer. Further, therapeutic vaccines for cervical cancer against HPV continue to evolve. All these findings pertaining to HPV could possibly decrease the incidence of cervical cancer in the near future. This review aims to give an overview of the HPV tests and products in use and those under trial currently.


HPV;DNA test;triage;cervical intraepithelial lesion;cervical cancer


  1. ASCUS-LSIL Traige Study (ALTS) Group (2003). Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol, 188, 1383-2.
  2. Baalbergen A, Smedts F, Ewing P, Snijders P, Meijer C, Helmerhorst T (2012). HPV-type has no impact on survival of patients with adenocarcinoma of the uterine cervix. Gynecol Oncol, 128, 530-4.
  3. Baskaran P, Subramanian P, Rahman R, et al (2013). Perceived susceptibility, and cervical cancer screening benefits and barriers in Malaysian women visiting outpatient clinics. Asian Pac J Cancer Prev, 14, 7693-9.
  4. Bencomo-Alvarez A, Limones-Perches I, Suarez-Rincon A, et al (2012). Human papillomavirus viral load in cervical intraepithelial neoplasia as a prognostic factor in a mexican population. Genetics Molecular Res, 11, 4720-7.
  5. Campitelli M, Jeannot E, Peter M, et al (2012). Human papillomavirus mutational insertion: Specific marker of circulating tumor DNA in cervical cancer patients. PLOS One, 7, 1-5.
  6. Cassel A, Barcellos R, Silva C, Almeida S, Rossetti M (2014). Association between human papillomavirus (HPV) DNA and micronuclei in normal cervical cytology. Genet Mol Biol, 37, 360-3.
  7. Castro S, Fernandez A, Gonzalez M, TeresaSaranDiez M, CidLama A, AlvarezMartin M, et al (2013). Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA. J Med Virol, 85, 1063-8.
  8. Cortes-Gutierrez E, Davila-Rodriguez M, Vargas-Villarreal J, Hernandez-Garza F, Cerda-Flores R (2010). Association between human papilloma virus-type infections with micronuclei frequencies. Prague Medical Report, 111, 35-1.
  9. Cuzick J, Szarewski A, Cubie H, et al (2003). Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet, 362, 1871-6.
  10. Das P, Thomas A, Mahantshetty U, Shrivastava S, Deodhar K (2012). HPV genotyping and site of viral integration in cervical cancers in indian women. PLoS ONE, 7, 41012.
  11. Eijsink J, Lendvai A, Deregowski V, et al (2012). A four-gene methylation marker panel as triage test in high- risk human papillomavirus positive patients. Int J Cancer, 130, 1861-9.
  12. Enerly E, Olofsson C, Nygard M (2013). Monitoring human papillomavirus prevalence in urine samples: A review. Clin Epidemiol, 5, 67-9.
  13. Faruk M, Murat M (2014). Cervical premalignant lesions and their management. J Turk Ger Gynecol Assoc, 15, 109-1.
  14. Harper D, Franco E, Wheeler C, Ferris D, Jenkins D, Schuind A, et al (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet, 364, 1757-5.
  15. Ioannis N, Demetrios GS (2014). The paediatric story of human papillomavirus (review). Oncology Letters, 8, 502-6.
  16. Jeronimoa J, Castlea P, Herrerob R, Burkc R, Schiffmana M (2003). HPV testing and visual inspection for cervical cancer screening in resource-poor regions. Int J Gynecol Obstet, 83, 311-3.
  17. Kalantari M, Calleja-Macias I, Tewari D, et al (2004). Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virology, 78, 12762-2.
  18. Kececioglu M, Seckin B, Baser E, et al (2013). Cost and effectiveness comparison of immediate colposcopy versus human papillomavirus DNA testing in management of atypical squamous cells of undetermined significance in turkish women. Asian Pac J Cancer Prev, 14, 511-4.
  19. Kim K, Park S, Ko K, Yi S, Cho Y (2014). Current status of human papillomavirus vaccines. Clin Exp Vaccine Res, 3, 168-5.
  20. Knoff J, Yang B, Hung C, Wu T (2014). Cervical cancer: Development of targeted therapies beyond molecular pathogenesis. Curr Obstet Gynecol Rep, 3, 18-2.
  21. Leal-Garza C, Cerda-Flores R, Leal-Elizondo E, Cortes-Gutierrez E (2002). Micronuclei in cervical smears and peripheral blood lymphocytes from women with and without cervical uterine cancer. Mutation Res, 515, 57-2.
  22. Li N, Silvia Franceschi S, Howell-Jones R, Snijders P, Clifford G (2010). Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer, 128, 927-5.
  23. Majid S, Teng S, Malik I, et al (2014). Estimation of human papilloma virus DNA in urine specimens as a marker for cervical cancer at an early stage. Int J Curr Microbiol App Sci, 3, 698-1.
  24. Marco Noventa M, Ancona E, et al (2014). Usefulness, methods and rationale of lymph nodes HPV-DNA investigation in estimating risk of early stage cervical cancer recurrence: A systematic literature review. Clin Experimental Metastasis, 31, 853-7.
  25. Markowitz L, Hariri S, Lin C, et al (2013). Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the united states, national health and nutrition examination surveys, 2003-2010. J Infect Disease, 208, 385-3.
  26. Mayrand M, Duarte-Franco E, Rodrigues I, et al (2007). Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med, 357, 1579-8.
  27. Mirabello L, Schiffman M, Ghosh A, et al (2013). Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer, 132, 1412-2.
  28. Nicolas Wentzensen N, Sherman M, Schiffman M, Wang S (2008). Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science. Gynecol Oncol, 112, 293-9.
  29. Ogilvie G, Krajden M, Niekerk D, Martin R, Ehlen T, Ceballos K, et al (2012). Primary cervical cancer screening with HPV testing compared with liquid-based cytology: Results of round 1 of a randomised controlled trial-the HPV FOCAL study. B J Cancer, 107, 1917-4.
  30. Othman N, Hayati Othman N (2014). Detection of human papillomavirus DNA in routine cervical scraping samples: Use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev, 15, 2245-9.
  31. Patel D, Rozek L, Colacino J, Van Zomeren-Dohm A, Ruffin M, Unger E, et al (2012). Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. J Virol Methods, 184, 84-2.
  32. Persson M, Elfstrom M, Wendel S, Weiderpass E, Andersson S (2014). Triage of HR-HPV positive women with minor cytological abnormalities: A comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study. PLOS ONE, 9, 1-8.
  33. Pimple S, Shastri S (2014). Comparative evaluation of human papilloma virus-DNA test verses colposcopy as secondary cervical cancer screening test to triage screen positive women on primary screening by visual inspection with 5% acetic acid. Ind J Cancer, 51, 117-3.
  34. Rossi P, Benevolo M, Vocaturo A, Caraceni D, Ciccocioppo L, Frega A, et al (2013). Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: A follow-up study. PLOS ONE, 8, 57600.
  35. Schmitt M, Depuydt C, Benoy I, et al (2013). Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions. Cancer Epidemiol Biomarkers Prev, 22, 406-4.
  36. Shalini L, James P, Nancy B, et al (2002). Evaluation of human papillomavirus testing in primary screening for cervical abnormalities Comparison of sensitivity, specificity, and frequency of referral. JAMA, 288, 1749-7.
  37. Trimble C, Frazer I (2009). Development of therapeutic HPV vaccines. Lancet Oncol, 10, 975-0.
  38. Vasiljevic N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A (2014). Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in highrisk HPV positive women. Gynecol Oncol, 132, 709-4.
  39. Wentzensen N, Vinokurova S, Doeberitz M (2004). Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res, 64, 3878-4.
  40. Widschwendter A, Blassnig A, Wiedemair A, et al (2003). Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Letters, 202, 231-9.
  41. Woodman C, Collins S, Young L (2007). The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer, 7, 11-2.
  42. Xu B, Chotewutmontri S, Wolf S, Klos U, Schmitz M (2013). Multiplex identification of human papillomavirus 16 DNA integration sites in cervical carcinomas. PLOS ONE, 8, e66693.

Cited by

  1. Does Cervical Screening in Young Women Aged 20-25 Years Lead to Unnecessary and Harmful Interventions? vol.16, pp.15, 2015,
  2. Decline of mortality from cervical cancer vol.71, pp.suppl 1, 2018,
  3. Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women vol.19, pp.1, 2019,